Abstract
Prophyllactic HPV vaccines are efficacious in preventing persistent infections by vaccine-HPV types and related cervical disease. The maximum effect is achieved in women who are not exposed to HPV vaccine types at the time of vaccination (HPV DNA negative women). Todays published data demonstrate equal clinical vaccine efficacy in women between 15 and 26 years and women between 24 and 45 years. The public health effect of vaccinating women older than 25 years is not clear yet, but may be smaller than after vaccination of adolescents. Unresolved issues are duration of protection and long-term preventive effects after treatment of HPV-related disease or natural clearance of HPV infection. Furthermore, it remains difficult to define subgroups of older women who would benefit from the vaccine. It may be that older women exposed to HPV or who are being treated for HPV related disease will benefit most at long term. This needs longer follow-up of vaccinated women and more detailed analysis of data from vaccine trials.
Keywords: HPV, vaccine, cervical neoplasia, adult women, prevention, review HPV vaccination in adult women
Current Cancer Therapy Reviews
Title: HPV Vaccination in Women Above 25 Years: Reasons Why?
Volume: 6 Issue: 2
Author(s): W. Poppe, PH. Simon, W. Tjalma and M. De Ridder
Affiliation:
Keywords: HPV, vaccine, cervical neoplasia, adult women, prevention, review HPV vaccination in adult women
Abstract: Prophyllactic HPV vaccines are efficacious in preventing persistent infections by vaccine-HPV types and related cervical disease. The maximum effect is achieved in women who are not exposed to HPV vaccine types at the time of vaccination (HPV DNA negative women). Todays published data demonstrate equal clinical vaccine efficacy in women between 15 and 26 years and women between 24 and 45 years. The public health effect of vaccinating women older than 25 years is not clear yet, but may be smaller than after vaccination of adolescents. Unresolved issues are duration of protection and long-term preventive effects after treatment of HPV-related disease or natural clearance of HPV infection. Furthermore, it remains difficult to define subgroups of older women who would benefit from the vaccine. It may be that older women exposed to HPV or who are being treated for HPV related disease will benefit most at long term. This needs longer follow-up of vaccinated women and more detailed analysis of data from vaccine trials.
Export Options
About this article
Cite this article as:
Poppe W., Simon PH., Tjalma W. and De Ridder M., HPV Vaccination in Women Above 25 Years: Reasons Why?, Current Cancer Therapy Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339410791202547
DOI https://dx.doi.org/10.2174/157339410791202547 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer
Current Cancer Therapy Reviews Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Targeting Protein Degradation in the Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Diagnostic Usefulness of Tumor Markers in the Thyroid Cytological Samples Extracted by Fine-Needle Aspiration Biopsy
Endocrine, Metabolic & Immune Disorders - Drug Targets ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Chemical Biology: Past, Present and Future
Current Chemical Biology Drug Metabolism and Individualized Medicine
Current Drug Metabolism Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism Patent Selections:
Recent Patents and Topics on Imaging (Discontinued) Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment
Current Drug Targets Evolutionary Plasticity of Vertebrate Hox Genes
Current Genomics Impact of COVID-19 on Gender Equality, Sexual and Reproductive Health Rights of Adolescent Girls and Young Women: A Narrative Review
Current Women`s Health Reviews Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Editorial (Thematic Issue: Nanosystems: An Innovative Tools for Medicinal Chemistry)
Current Topics in Medicinal Chemistry